Companies
RetinAI
its AI-based OCT analytics platform (RetinAI Discovery) was acquired by EssilorLuxottica, a transaction reported in October 2025, positioning the technology within a much larger eye-health and eyewear business.
- Country
- Switzerland
Commercial
RetinAI Discovery OCT analytics
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $15.7 million in total funding across 3 rounds | thecompanycheck.com |
| Headcount | More than 60 employees as of October 2025 | unibe.ch |
| Certification | CE-marked for clinical use under EU MDR 2017/745 for multiple AI models and platforms including RetinAI OCT Atlas | retinai.com |
| Regulatory approval | FDA 510(k) cleared platform (RetinAI Discovery) | glance.eyesoneyecare.com · retinai.com |
| Headquarters | Bern, Switzerland | retinai.com |
| Production site | Bern, Switzerland (HQ) and Boston, United States (subsidiary) | retinai.com |
Independent sources: glance.eyesoneyecare.com · thecompanycheck.com · unibe.ch
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI optical coherence tomography screening | diagnostics-medtech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.